CHANGE MY LOCATION
Business and Finance
Business News
McCain, Obama trade barbs in town hall debate- John McCain dismissively called rival Barack Obama "that one," Obama mocked McCain's "Straight Talk Express," and both left the debate stage to return to the campaign trail Wednesday.
Analysis: Obama gains, McCain seeks game-changer- Barack Obama made strides toward easing voters' concerns about his candidacy in Tuesday night's debate. John McCain, despite raising pointed questions about his rival's readiness, didn't create the game-changing moment he'll need between now and Election Day.
Asian stocks plunge on unabated credit market woes- Asian stock markets tumbled Wednesday, with Japan's Nikkei index sinking nearly 10 percent, as recent steps by the world's major economies to fortify credit markets failed to stem fears that the spreading financial crisis could spawn a global recession.
- With financial markets still tumbling, the Federal Reserve is signaling that it might cut interest rates after a series of bold steps by federal regulators failed to stem the slide. Neither presidential candidate offered a solution.
- U.S. and Japanese researchers are among the favorites to win the Nobel Prize in chemistry, but don't expect any recent discoveries to get the nod.
- A U.S. military officer warned Pentagon officials that an American detainee was being driven nearly insane by months of punishing isolation and sensory deprivation in a U.S. military brig, according to documents obtained by The Associated Press.
- Hurricane Norbert strengthened into a powerful Category 2 storm over the Pacific Ocean and forecasters warned that it could reach Mexico's Baja California peninsula by the weekend.
Travis Barker thankful to be alive after jet crash- Former Blink-182 drummer Travis Barker, who always has been afraid of flying, says he's glad to be alive after suffering severe burns in a fiery plane crash last month.
Bosox-Rays renew rivalry, Manny in middle of NLCS- Exactly why the Boston Red Sox and Tampa Bay Rays tangle so much is hard to tell. Blame it on a high-and-tight pitch here, a hard slide there. Whatever, this much is true: The teams playing in the AL championship series sure get into a lot of scraps. "There's no hatred," injured Red Sox pitcher Curt Schilling insisted Tuesday in an e-mail to The Associated Press.
BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor
BSI-201 demonstrated an excellent safety profile and evidence of clinical benefit in 65% (59 of 90) patients in the combined Phase 1/1b study populations, consisting of heavily pre-treated patients with advanced solid tumors. Furthermore, significant (> 80% relative to baseline) and prolonged (> 4 days duration) PARP inhibition in blood cells was observed after multiple doses of BSI-201.
"These clinical results show that BSI-201 can be administered safely, both
alone and in combination with other chemotherapeutic agents, across a broad
range of tumors. Moreover, we are extremely encouraged that the synergistic
effects of a PARP inhibitor, in combination with other standard-of-care
chemotherapeutic treatments, are supported by these clinical observations,"
said
Active BSI-201 Phase 2 Program in Solid Tumors
The company is currently conducting a randomized Phase 2 trial of BSI-201 in triple-negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain cancer in adults. BSI-201 is also being evaluated by Memorial Sloan-Kettering Cancer Center investigators as a monotherapy for patients whose ovarian cancer is linked to a hereditary BRCA genetic defect. Finally, the company is working with the NCI-sponsored research group, the Gynecologic Oncology Group, to test BSI-201 in patients with advanced, persistent or recurrent uterine cancer. The Phase 2 program has been guided by gene expression data demonstrating PARP up-regulation in targeted tumor classes.
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials, including studies in breast, uterine, brain and ovarian cancers.
|
|
More Business_and_Finance Releases
(RIMM): BlackBerry Takes the World by Storm with Verizon Wireless and Vodafone
(VZ): Verizon and i-SAFE Partner for Second Cyber Safety Week in Colorado
